Connect with us

Media OutReach

DHL Global Forwarding Adds to Its Asia Pacific’s Life Science and Healthcare Capabilities with Dual-Certified Cold Chain Facility in Malaysia

Published

on

  • First forwarder with dual-certified facility within Kuala Lumpur International Airport Free Commercial Zone for 15–25°C and 2–8°C storage, with Good Distribution Practice qualifications
  • Sets new benchmark in pharmaceutical logistics with reefer truck transfers, secure cages, and eco-friendly infrastructure.
  • Strengthens DHL’s network of 37 Air GxP and 12 IATA CEIV Pharma-certified stations across Asia-Pacific, reinforcing its leadership in providing compliant and sustainable healthcare logistics.

SINGAPORE – Media OutReach Newswire – 27 August 2025 – To meet the growing demand for temperature-sensitive pharmaceutical logistics, DHL Global Forwarding continues to enhance its cold chain capabilities in Malaysia, being the first forwarder to offer a cold chain facility certified for both 15–25°C and 2–8°C storage within the Kuala Lumpur International Airport (KLIA) Free Commercial Zone. Spanning over 38,000 square feet, the state-of-the-art facility is accorded both the DHL Air GxP certification and the IATA CEIV Pharma certification, delivering unmatched flexibility and regulatory compliance for Life Science and Healthcare customers.

DHL Global Forwarding Malaysia Facility

Based on the World Health Organization’s Good Distribution and Storage Practices, the DHL Air GxP certification is a baseline requirement across all DHL pharma stations to ensure upholding of stringent quality and compliance standards. Complementing this is the IATA CEIV Pharma certification, a globally recognized standard that validates DHL’s capabilities in handling high-value, time- and temperature-sensitive pharmaceutical shipments.

“Malaysia is strategically located to serve as a regional hub for global medical technology companies, and the fast-growing market is expected to increase at a CAGR of 8.5 per cent from 2023 to 2028, reaching a market volume of US$4.5 billion by 2028,” said Praveen Gregory, Managing Director, Singapore, Malaysia and Brunei, DHL Global Forwarding. “Our cold chain infrastructure in KLIA has consistently delivered high standards in pharmaceutical logistics since its launch in 2023, and as demand across Asia Pacific accelerates, we are ready to lead with best-in-class facilities and expertise to support our customers.”

Comprehensive solutions to cater to diverse needs and maintain cold chain integrity

The facility comprises:

  • Dedicated cold rooms: 1,040 square feet for 15–25°C storage and 504 square feet for 2–8°C storage, supporting up to 105 EU pallets
  • Dual secure cages: Over 2,400 square feet of high-security storage with 24/7 CCTV surveillance and restricted access.
  • Advanced Environment Monitoring System (EMS): 100% automated real-time storage temperature monitoring via a dual system (Testo Saveris and UniBot), with data stored for one year.
  • Eco-friendly infrastructure: R448A refrigerant, food-grade epoxy flooring, airtight doors, and energy-efficient compressors.
  • Operational excellence: 24/7 operations with dedicated customs brokerage and value-added services such as buyer consolidation, cross-docking, and LD3 container charging.
  • Fully temperature-mapped carve-out site: Designated area that has undergone a thorough temperature mapping process, specifically designed to store or handle temperature-sensitive products
  • Dehumidification system: Tailored for pharmaceutical application between the range of 55% to 70%Rh

DHL is also the only forwarder in KLIA offering reefer truck transfers from pick-up to terminal arrival and delivery. This service ensures cold chain integrity is maintained throughout the journey and minimizes third-party handling, which in turn reduces turnaround time. It also enhances cargo security and ensures compliance with Good Distribution Practice (GDP) standards.

To ensure all shipments are handled with utmost care and in compliance with the highest industry standards, all cold-chain shipments are handled by a dedicated team of Life Sciences Specialists who have completed the training and are certified. These staff undergo annual training to stay ahead of evolving industry requirements, armed with vital tools and knowledge needed to understand and meet both customer and regulatory expectations. In addition to implementing a specialized training program aligned with IATA regulatory standards across its key GxP facilities, DHL’s CIF Certified Life Sciences Specialist (CLSS) program equally provides a comprehensive curriculum of mandatory training sessions, functional courses, and material to build deep expertise in this highly specialized industry.

DHL’s commitment to green logistics is also evident in the KLIA facility’s design. The facility is built using CFC- and HCFC-free materials and is fitted with energy-saving compressors and low-noise, low-emission generators. The company is also exploring mobile freezer units capable of operating at -20°C, as well as expanding its service portfolio to include frozen commodities such as vaccines, meat, and industrial chemicals.

Asia Pacific: Fast-Growing Strategic Hub for Healthcare Logistics

Asia Pacific is rapidly emerging as a global center for pharmaceutical innovation, manufacturing, and distribution. According to an industry trend report by Data Bridge Market Research, the region’s healthcare logistics market is forecasted to grow from USD 17.6 billion in 2022 to USD 29.5 billion by 2030, at a CAGR of 7.1%. This growth is driven by aging populations, rising chronic disease prevalence, and increasing demand for biologics, vaccines, and clinical trials.

DHL is uniquely positioned to support this growth, with a robust and strategically distributed cold chain network across Asia Pacific. As part of its Strategy 2030: Accelerating Sustainable Growth, DHL Group has identified Life Sciences and Healthcare (LSH) as a key growth sector and introduced a new “DHL Health Logistics sector brand to drive cross-divisional growth. This reflects a broader global trend in which logistics is increasingly recognized as a critical enabler of healthcare access and patient outcomes. Earlier this year, DHL Group also announced a €500 million investment in Life Sciences infrastructure across Asia Pacific, including 300,000 square meters of fully compliant storage in 15 countries – a move that reinforces its regional logistics leadership.

Currently, DHL operates 37 Air GxP-certified stations and 12 IATA CEIV Pharma-certified stations in the region, including key hubs in Kuala Lumpur, Singapore, Tokyo, Seoul, Sydney, and Shanghai. These facilities are meticulously set up to meet the highest standards of pharmaceutical logistics, ensuring temperature integrity, regulatory compliance, and operational excellence. Each certified station is staffed by trained Life Sciences Specialists and supported by integrated supply chain capabilities, including temperature-controlled transportation, customs brokerage, real-time shipment monitoring, and post-shipment investigations.

As the healthcare industry continues to evolve, DHL remains steadfast in its mission to deliver resilient, compliant, and future-ready logistics solutions. With its expanding footprint, certified expertise, and commitment to innovation, it is well-positioned to be the logistics partner of choice for life sciences companies across Asia Pacific—ensuring that critical healthcare products reach patients safely, efficiently, and sustainably.
Hashtag: #DHL

The issuer is solely responsible for the content of this announcement.

DHL – The logistics company for the world​

DHL is the leading global brand in the logistics industry. Our DHL divisions offer an unrivalled portfolio of logistics services ranging from national and international parcel delivery, e-commerce shipping and fulfillment solutions, international express, road, air and ocean transport to industrial supply chain management. With approximately 400,000 employees in more than 220 countries and territories worldwide, DHL connects people and businesses securely and reliably, enabling global sustainable trade flows. With specialized solutions for growth markets and industries including technology, life sciences and healthcare, engineering, manufacturing & energy, auto-mobility and retail, DHL is decisively positioned as “The logistics company for the world”.

DHL is part of DHL Group. The Group generated revenues of approximately 84.2 billion euros in 2024. With sustainable business practices and a commitment to society and the environment, the Group makes a positive contribution to the world. DHL Group aims to achieve net-zero emissions logistics by 2050.

Advertisement

Media OutReach

Zuellig Pharma Acquires Cialis® (Tadalafil) from Lilly in three additional markets in Asia

Published

on

SINGAPORE – Media OutReach Newswire – 12 March 2026 – Zuellig Pharma, a leading healthcare solutions company in Asia, today announced that it has acquired all rights, title, and interest in and to Cialis® (Tadalafil), a leading men’s health product from Eli Lilly and Company (“Lilly”) in Hong Kong, Macau and South Korea.

Following the acquisition, Zuellig Pharma will now own the trademarks, marketing authorizations and license manufacturing know-how for Cialis®, a treatment for erectile dysfunction (ED) and benign prostatic hyperplasia (BPH), in 11 markets in Asia, with the expansion of its ownership into three additional markets beyond the original eight. Zuellig Pharma will also continue to promote and distribute the brand in these markets.

The expanded ownership of Cialis® will widen accessibility of the drug to a significant population of men in Asia who are affected by ED and BPH. The acquisition also aligns with Zuellig Pharma’s strategic priority of building a strong portfolio of owned prescription healthcare products as an integrated healthcare solutions company.

“Our acquisition of Cialis® in three additional markets builds on the strong foundation we established two years ago and highlights our proven success in scaling trusted brands effectively through our commercial capabilities and deep expertise. As we broaden our footprint, we remain focused on delivering sustainable growth and advancing our purpose of making in-demand healthcare solutions more accessible to communities in Asia,” said John Graham, CEO of Zuellig Pharma.
Hashtag: #ZuelligPharma #EliLillyandCompany #Cialis #MensHealth #Healthcare #Pharmaceuticals


The issuer is solely responsible for the content of this announcement.

About Zuellig Pharma

Zuellig Pharma is a leading healthcare solutions company in Asia, and our purpose is to make healthcare more accessible to the communities we serve. We provide world-class distribution, commercialization, and clinical trial support services, underpinned by a strong culture of innovation to support the growing healthcare needs in this region. The company was founded a hundred years ago and has grown to become a multibillion-dollar business covering 18 markets with over 12,000 employees. Our people serve more than 200,000 medical facilities and work with over 450 clients, including the top 20 pharmaceutical companies in the world.

Continue Reading

Media OutReach

Ingdan Powers Embodied AI with Humanoid-Style Brain-Cerebellum Chipset to Boost Robotics Ecosystem

Published

on

HONG KONG SAR – Media OutReach Newswire – 12 March 2026 – Ingdan, Inc. (“Ingdan” or the “Company”, stock code: 400.HK; with its subsidiaries (the ”Group”)), a core supplier in the AI computing power supply chain and a leading application technology solutions provider, announces continued progress in strengthening its humanoid robotics ecosystem through an integrated embodied intelligence IC product matrix, supporting the industry’s transition toward large‑scale commercialization.

2026 is widely regarded as a milestone year for humanoid robotics, in which humanoid robots transition from laboratory prototypes and demonstration performances to large‑scale mass production. At CES in January, NVIDIA announced the commercial launch of its physical‑AI core platform Jetson Thor. Tesla is scheduled to officially release the mass‑production engineering version of its Optimus (V3) humanoid robot by the end of March, with plans to initiate million‑unit‑level production lines by the end of 2026—an inflection point widely regarded as the “Model 3 moment” of the humanoid robotics industry. At the same time, Chinese robotics companies such as AGIBOT, Unitree, and Fourier Intelligence have already deployed products at scale in warehousing and logistics scenarios.

Against this backdrop, the upstream hardware focus of the humanoid robotics industry is increasingly converging on “Brain-Cerebellum” collaboration and low‑latency, multi‑joint real‑time control, which are essential to achieving coordinated, smooth, and human‑like robotic motion. During the CMG Spring Festival Gala, robots from multiple companies demonstrated complex coordinated movements and dexterous hand operations, further highlighting the value of this technical direction.

D‑Robotics, originating from the AIoT and robotics division of Horizon Robotics, focuses on edge‑side embodied intelligence solutions characterized by high computing power, integrated computation and control, and low latency. Leveraging its parent company’s long‑term experience in intelligent driving, D‑Robotics has established a precise position in humanoid robot “Brain-Cerebellum” coordination and real‑time joint control.

In November 2025, D‑Robotics unveiled its flagship robotics computing platform S600, with an official release planned for the end of the first quarter of 2026. The S600 platform features a highly integrated humanoid‑style “Brain-Cerebellum” chipset architecture. Its “Brain” configuration combines an 18‑core A78AE CPU with a proprietary Nash‑architecture BPU, delivering 560 TOPS (INT8) edge computing power and supporting efficient deployment of VLA, VLM, LLM, and locomotion models. Its “Cerebellum” configuration integrates a 6‑core R52+ MCU, providing high‑reliability, real‑time motion control.

By integrating CPU, BPU, and real‑time MCU capabilities into a single SoC, S600 enables a closed‑loop architecture encompassing perception, decision‑making, and real‑time action control. This design addresses a key industry challenge in which many edge AI processors lack embedded real‑time MCUs and rely on external controllers, resulting in excessive latency. The integrated MCU supports high‑frequency, high‑precision PWM signal generation based on FOC algorithms, enabling precise motor control and contributing to stable rhythm and natural gait.

The S600 platform has been adopted by multiple robotics companies such as Fourier Intelligence, Booster Robotics, X Square Robot, and ROBOTERA, supporting applications that require stable multi‑joint coordination and smooth motion performance.

Ingdan, Inc. (00400.HK) is a core supplier in the AI computing power supply chain and an application technology solutions provider covering both AI infrastructure and AI intelligent terminals. The Company represents a broad portfolio of international semiconductor manufacturers, including NVIDIA, Xilinx, Intel, AMD, and SanDisk, as well as numerous domestic chip vendors. It serves hundreds of robotics manufacturers and Tier‑1 customers and has formed a comprehensive embodied intelligence ecosystem.

D‑Robotics is a core product line Ingdan distributes . Building on D‑Robotics’ products and combined with its own technical services—such as multi‑sensor fusion development, real‑time closed‑loop tuning, Quantization‑Aware Training (QAT) support, simulation testing, and modular SOM customization—the Group has supported sophisticated customers including Galbot and ROBOTERA, continuously enriching the robotics industry ecosystem.

Looking ahead, Ingdan will continue to focus on the humanoid robotics sector. Leveraging an IC product matrix centered on NVIDIA Jetson and D‑Robotics platforms, the Company aims to further strengthen its AI intelligent terminal capabilities and continue supporting the iterative development of embodied intelligence products.

For investor and media enquiries
Please email to **@****an.com

Hashtag: #Ingdan #Chips #humanoid #D‑Robotics #NVIDIA #Tech

The issuer is solely responsible for the content of this announcement.

Ingdan, Inc.

Ingdan, Inc. (00400.HK) is a core supplier in the AI computing power supply chain and an application technology solutions provider covering both AI infrastructure and AI intelligent terminals. The Company represents a broad portfolio of international semiconductor manufacturers, including NVIDIA, Xilinx, Intel, AMD, and SanDisk, as well as numerous domestic chip vendors. It serves hundreds of robotics manufacturers and Tier‑1 customers and has formed a comprehensive embodied intelligence ecosystem.

Continue Reading

Media OutReach

Snow, Ice, and Performance: 2026 Changan Global Testing Season Arrives in Europe with Back-to-Back Winter Events

Published

on

  • European dealers and journalists experienced the CHANGAN DEEPAL S05 AWD at 2026 Changan Global Testing Season this February.
  • With intelligent AWD and advanced ADAS, the CHANGAN DEEPAL S05 AWD offered uncompromising safety and control on winter roads.

Saalfelden, Austria – Media OutReach Newswire – 12 March 2026 – Following extreme cold tests in Yakeshi, China, the 2026 Changan Global Testing Season made its European debut this February with the Changan Winter Experience in Courmayeur and the Winter Test Drives in Saalfelden. The all-electric CHANGAN DEEPAL S05 AWD was tested on snow and ice—familiar conditions for European drivers—offering dealers and journalists an immersive introduction to Changan’s electric mobility vision through dynamic drives.

Three-time Olympic gold medalist and Milano Cortina 2026 Ambassador Deborah Compagnoni joined the event in Courmayeur, testing the CHANGAN DEEPAL S05 AWD. Her career—defined by determination, control, and reliability—reflects Changan’s core values. “I felt that the principles of trajectory and speed in skiing apply to driving. With this model, you gain confidence on challenging terrain,” she said.

Snow-Validated Performance: The CHANGAN DEEPAL S05 AWD

Tested in Europe, the CHANGAN DEEPAL S05 AWD demonstrated controllable dynamics, reliable traction, and enhanced safety—highlighting its cutting-edge AWD and ADAS. The system adapts seamlessly: ECO/COMFORT modes prioritize RWD efficiency, while AWD will engage automatically when sensors detect slip, high torque demand, or extreme cold below -25°C. SPORT mode delivers permanent 50:50 torque for sharper response. SNOW mode maintains balanced torque with optimized slip control for confident driving on low-grip surfaces.

The intelligent AWD system delivers up to 320 kW power, 502 Nm torque, and 0–100 km/h acceleration in 5.5 seconds. It also improves hill climbing with a 40% gradient capability, ensures stability by actively balancing power to prevent skidding, and enables safer cornering at higher speeds through optimized grip and vehicle dynamics.

Changan Standard: Proven in the Alps, Bound for the World

Changan Standard is defined by a principle: forged in extremes, built for every day. From Yakeshi to the Alps, the test environments are selected to verify specific performance attributes—safety technologies, chassis response, all-wheel-drive calibration, and ADAS in low-grip scenarios. The objective of 2026 Global Testing Season is not to demonstrate extremes, but to confirm consistency: that the same level of safety, control, and stability demonstrated will be replicated in Mexico, Thailand, and Saudi Arabia.

Hashtag: #Changan

The issuer is solely responsible for the content of this announcement.

Continue Reading

Trending